Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C - V | Alive

Total Raised


Last Raised

$880K | 1 yr ago

About PRISM BioLab

PRISM BioLab is a Japanese drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions. The company has developed a platform technology to modulate inter-cellular protein-protein interactions using peptide mimetic small molecules and found various hit compounds including PRI-724, which (in animal models) has reversed the formation of excessive fibrous connective tissue, demonstrating its potential to treat fibrosis in several indications including Hepatitis C and IPF.

PRISM BioLab Headquarters Location

Shonan Eye Park 2-26-1, Muraokahigashi

Fujisawa, 251-0012,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PRISM BioLab

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PRISM BioLab is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

PRISM BioLab Patents

PRISM BioLab has filed 13 patents.

The 3 most popular patent topics include:

  • Diseases of liver
  • Glycoproteins
  • Hepatology
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immune system, Immunology, Cancer treatments, Transcription factors


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immune system, Immunology, Cancer treatments, Transcription factors



Latest PRISM BioLab News

Prism offers Genentech peptide mimetic small-molecules library for multitarget collaboration

Jan 11, 2022

Jan. 11, 2022 Prism Biolab Co. Ltd. has added Genentech Inc. , a unit of Roche Holding AG, to the list of users for its peptide mimetic small-molecules library after signing a multitarget research collaboration and licensing agreement. Under the agreement, Tokyo-based Prism Biolab will open its Pepmetics Library, a library of peptide mimetic small molecules, to screen against targets selected by Roche and Genentech. “Once Genentech identifies hit compounds, they can elect to further develop and commercialize the compounds,” Dai Takehara, president and CEO at Prism Biolab, told BioWorld. Financially, the Japanese company will receive an up-front payment, success-based milestone payments and royalties on future net sales. Specific terms were not disclosed. Prism Biolab will now begin drug discovery with Genentech and Roche with the aim of developing new drugs, but neither Prism Biolab nor Roche provided a development timetable for the first drug in the collaboration. “Over the next few years, Roche and Genentech can nominate targets to screen,” a Roche spokesperson told BioWorld. “Upon identification of hit compounds, Roche and Genentech may elect to further develop and commercialize the compounds.” The deal enables Prism Biolab to add to the number of users for its drug discovery platform. “We have a drug discovery platform of peptide mimetic small molecules, and provide this platform to global pharmaceutical companies to generate hit and lead compounds for drugs,” said Takehara. The collaboration enables Genentech and Roche to utilize the platform as well as their research capabilities to generate new drugs, he added. The deal with Prism Biolabs gives Genentech and Roche a new tool to tackle currently undruggable target spaces. “Novel modalities and enabling technologies to expand the druggable target space are one of the key areas of focus for our partnering efforts for drug discovery,” said the Roche spokesperson. Genentech and Roche have inked more than 15 discovery partnerships in this space across a range of therapeutic modalities, such as small molecules, proteins, gene therapy and cell therapy, to tackle targets both at the protein and the RNA level the spokesperson added. Founded in 2006, Prism has developed Pepmetics Technology, a small-molecule drug discovery platform. The molecules are designed to mimic ?-helix or ?-turn peptides, using a unique stable scaffold with corresponding dihedral angles. Those motifs are essential for protein-protein interactions within the cell, particularly for transcription and translation, said the company. Currently, Prism is in the clinic with two clinical-stage assets for cancer and fibrosis that have been developed and licensed using the platform. Prism is also collaborating with pharmaceutical companies both within and outside Japan to discover new drug targets. One of those collaborations is with Guildford, Conn.-based Inveniai LLC. Prism partnered with the company in September 2020 to develop a pipeline of therapeutic candidates addressing diseases in the gut that are associated with the dysfunction of the gut-brain-axis and inflammasome dysregulation. That collaboration will use Alphameld, Inveniai’s own platform, to identify and validate relevant targets, to develop transformative therapies for gut-related diseases. While Prism will also contribute its platform to design small-molecule candidates against targets validated by Inveniai, the U.S. company will pursue human proof-of-concept for all candidate drugs. Prism raked in up-front payments, development milestones and single-digit royalties under that deal. The Japanese company currently has two CREB-binding protein (CBP)/?-catenin inhibitors in clinical trials. “E7-386, which was licensed to Eisai Co. Ltd. for oncology, is in a phase I clinical trial and achieved clinical proof of concept, as announced in November 2021. Another CBP/?-catenin inhibitor, PRI-724, licensed to Ohara Pharmaceuticals Co. Ltd. to treat hepatic fibrosis, is in a phase IIa clinical trial,” said Takehara.

PRISM BioLab Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PRISM BioLab Rank

  • When was PRISM BioLab founded?

    PRISM BioLab was founded in 2006.

  • Where is PRISM BioLab's headquarters?

    PRISM BioLab's headquarters is located at Shonan Eye Park, Fujisawa.

  • What is PRISM BioLab's latest funding round?

    PRISM BioLab's latest funding round is Series C - V.

  • How much did PRISM BioLab raise?

    PRISM BioLab raised a total of $33.14M.

  • Who are the investors of PRISM BioLab?

    Investors of PRISM BioLab include Eisai, DBJ Capital, Daiwa Corporate Investment, Gemseki, Healthcare Innovation and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.